Resveratrol Attenuates Intermittent Hypoxia-Induced Macrophage Migration to Visceral White Adipose Tissue and Insulin Resistance in Male Mice

Alba Carreras, Shelley X. L. Zhang, Isaac Almendros, Yang Wang, Eduard Peris, Zhuanhong Qiao, and David Gozal

Section of Pediatric Sleep Medicine, Department of Pediatrics, Comer Children’s Hospital, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637

Chronic intermittent hypoxia during sleep (IH), as occurs in sleep apnea, promotes systemic insulin resistance. Resveratrol (Resv) has been reported to ameliorate high-fat diet-induced obesity, inflammation, and insulin resistance. To examine the effect of Resv on IH-induced metabolic dysfunction, male mice were subjected to IH or room air conditions for 8 weeks and treated with either Resv or vehicle (Veh). Fasting plasma levels of glucose, insulin, and leptin were obtained, homeostatic model assessment of insulin resistance index levels were calculated, and insulin sensitivity tests (phosphorylated AKT [also known as protein kinase B]/total AKT) were performed in 2 visceral white adipose tissue (VWAT) depots (epididymal [Epi] and mesenteric [Mes]) along with flow cytometry assessments for VWAT macrophages and phenotypes (M1 and M2). IH-Veh and IH-Resv mice showed initial reductions in food intake with later recovery, with resultant lower body weights after 8 weeks but with IH-Resv showing better increases in body weight vs IH-Veh. IH-Veh and IH-Resv mice exhibited lower fasting glucose levels, but only IH-Veh had increased homeostatic model assessment of insulin resistance index vs all 3 other groups. Leptin levels were preserved in IH-Veh but were significantly lower in IH-Resv. Reduced VWAT phosphorylated-AKT/AKT responses to insulin emerged in both Mes and Epi in IH-Veh but normalized in IH-Resv. Increases total macrophage counts and in M1 to M2 ratios occurred in IH-Veh Mes and Epi compared all other 3 groups. Thus, Resv ameliorates food intake and weight gain during IH exposures and markedly attenuates VWAT inflammation and insulin resistance, thereby providing a potentially useful adjunctive therapy for metabolic morbidity in the context of sleep apnea. (Endocrinology 156: 437–443, 2015)
Materials and Methods

Animals

Adult male C57BL/6J mice from Jackson Laboratories (8 wk old, ~22 g) were housed in groups of 5 (to prevent isolation stress) in standard clear polycarbonate cages and allowed to acclimate to their surroundings. Mice were fed normal chow diet and water ad libitum and maintained in a 12-hour light, 12-hour dark cycle (light on 7 AM to 7 PM) at a constant temperature (26 ± 1°C). Mice were randomly assigned to IH exposures or room air (RA) conditions and to treatment with Resv or vehicle (Veh) (control) for 8 weeks.

Mice received drinking water containing 0.01% Resv (Sigma-Aldrich). This amount of Resv is approximately 10 times the amount found in 1 L of red wine and was initially dissolved in 0.4 mL of absolute ethanol and then added to 100 mL of drinking water. The Veh group received the same volume of drinking water containing an identical concentration of ethanol. All mice had free access to the drinking solution, and mice consumed 3–4 mL of the drinking fluid daily, with the daily consumption of Resv being 0.3–0.4 mg/mouse (ie, a relatively high dose of the compound with demonstrated efficacy) (39).

Animal experiments were performed according to protocols approved by the Institutional Animal Committee University of Chicago of the University of Chicago and are in close agreement with the National Institutes of Health Guide in the Care and Use of Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Intermittent hypoxia exposures

Mice were placed in identical commercially designed chambers (30 × 20 × 20 inches; Oxycycler A44XO; BioSpherix) operated under a 12-hour light, 12-hour dark cycle (7 AM to 7 PM) for a period of 8 weeks. Programmed gas concentrations were circulated into each chamber, and an internal O2 analyzer measured the O2 concentration continuously. Deviations from the fixed concentrations were automatically corrected by a computerized system of solenoid valves controlling gas outlets adding either N2 or O2. Ambient CO2 in the chamber was maintained at less than 0.01%, and humidity was also maintained at 40–50% by circulating the gas through a freezer and silica gel. Ambient temperature was kept at 26°C as described previously by Gozal and coworkers (1, 15) and Gozal et al (40). Mice were subjected for 12 hours during daylight to intermittent hypoxia/normoxia cycles of 3-minute duration (hypoxia, nadir of FiO2; 6.4% for 90 s alternating with normoxia [fractional inspired oxygen concentration, FiO2, 21%] for 90 s). This IH profile is associated with reproducible nadir of oxyhemoglobin saturations in the 65%–72% range. Normoxic (FiO2, 21% conditions were used during the 12-hour lights-off period. Control animals were exposed to circulating RA (FiO2, 21%) during daylight and lights-off period.

Food consumption and body weight

Food consumption per cage was registered daily, always at the same time of the day (middle of the light period). Animal food consumption was then calculated by dividing the daily cage chow use by the number of mice in the cage. Body weight was measured every other day always at the same time of the day (middle of the light cycle period). Body weight gain was determined by subtracting the body weight on first day of IH exposure from the body weight on subsequent days.

ELISA and insulin sensitivity assays

Mice were fasted for 3 hours (4–7 AM) with water available ad libitum and were then euthanized. Venous blood was collected into EDTA-containing tubes, immediately centrifuged in 4°C, and frozen at −80°C until further analyses. Blood glucose was immediately assessed using an OneTouch Ultra2 glucometer (Life Scan, Inc). Insulin and leptin assays were carried out using ELISA kits (Millipore) according to the manufacturer’s protocol. The linear range of the insulin assay was 0.2–10 ng/mL, with the limit of sensitivity at 0.2 ng/mL (35pM) and intra- and interindividual coefficients of variation up to 8.8% and 17.6%, respectively, at lower concentrations (ie, 0.32 ng/mL). Similarly for the leptin assay, the linear range was 0.2 up to 30 ng/mL with the sensitivity threshold at 0.05 ng/mL (~3.13pM). The intraassay variation coefficient was up to 1.7% at high concentrations of leptin (17.60 ng/mL) and 6.8% of interindividual coefficient of variation at low concentrations (ie, 1.66 ng/mL). The homeostatic model (HOMA) was then calculated as the product of glucose and insulin levels divided by 405.

Adipocyte insulin sensitivity was assessed in adipocytes derived from epididymal (Epi) and mesenteric (Mes) fat tissue depots as described previously (41). Briefly, primary adipocytes were isolated by collagenase digestion and flotation centrifugation. They were then incubated with insulin at various concentrations at 37°C for 10 minutes with gentle vortexing every 2 minutes. After 2 washes with cold Krebs-Ringer buffer, cells were lysed in Laemmli buffer and assessed using Western blot analysis for phosphorylated and total Akt (protein kinase B)
Isolation of stromal-vascular fraction (SVF) and flow cytometry analysis

Epi fat pads and Mes adipose tissues were dissected, isolated, and then minced in Krebs-Ringer buffer supplemented with 1% BSA followed by incubation with collagenase (1 mg/mL; Worthington Biochemical Corp) at 37°C for 45 minutes with shaking. Cell suspensions were filtered through a 100-μm mesh and centrifuged at 500 g for 5 minutes to separate floating adipocytes from the SVF pellet. SVF pellets were then resuspended in flow cytometry buffer (PBS plus 2% fetal bovine serum), and 10⁶ cells were used for staining with fluorescence-conjugate primary antibodies or control IgGs at 4°C for 30 minutes. Cells were then washed twice and analyzed with a flow cytometer (Canto II; BD Biosciences). Data analysis was performed using the FlowJo software (Tree Star). Adipose tissue macrophages were defined as F4/80⁺ and CD11b⁺ cells, from which M1 and M2 macrophages were identified as CD11c⁺ or CD206⁺ cells, respectively. Please see Table 1 for list of antibody reagents.

Statistical analysis

All values are expressed as mean ± SD. ANOVA procedures followed by post hoc tests and Student’s t tests were used to compare the results between 4 treatment groups as appropriate, using SPSS statistical software (version 21.0; SPSS, Inc). In all cases, 2-tailed P < .05 was considered to achieve statistical significance.

Results

Food intake and weight gain

Mice exposed to IH exhibited initial decreases in food intake that began within the first 24 hours after the initiation of IH and were followed by progressive recovery to control levels within the first week (n = 12/condition; Figure 1).

Table 1. Information on All Antibodies and Reagents Used in Current Study

<table>
<thead>
<tr>
<th>Treg</th>
<th>CD3-FITC</th>
<th>Clone 145-2C11</th>
<th>100306</th>
<th>Biolegend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD4-PE</td>
<td>Clone RM4-4</td>
<td>116006</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD8-APC/Cy7</td>
<td>Clone 53-6.7</td>
<td>100714</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD25-APC/Cy5.5</td>
<td>Clone PC61</td>
<td>102030</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>FoxP3-APC</td>
<td>Clone FJK-16s</td>
<td>17-5773</td>
<td>eBioscience</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Macrophages</th>
<th>CD11b-PB</th>
<th>Clone M1/70</th>
<th>101224</th>
<th>Biolegend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F4/80-PE/Cy7</td>
<td>Clone BM8</td>
<td>123113</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD11c-APC/Cy7</td>
<td>Clone N418</td>
<td>117324</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD206-PE</td>
<td>Clone C068C2</td>
<td>141705</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>Gr1-PerCP</td>
<td>Clone R66-8C5</td>
<td>108428</td>
<td>Biolegend</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WBC</th>
<th>CD3-FITC</th>
<th>Clone 145-2C11</th>
<th>100306</th>
<th>Biolegend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CD4-PE</td>
<td>Clone RM4-4</td>
<td>116006</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD8-APC/Cy7</td>
<td>Clone 53-6.7</td>
<td>100714</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>Gr1-PerCP</td>
<td>Clone R66-8C5</td>
<td>108428</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD115-APC</td>
<td>Clone AF598</td>
<td>135509</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD11b-PB</td>
<td>Clone M1/70</td>
<td>101224</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD4-PE</td>
<td>Clone RM4-4</td>
<td>116006</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD8-APC/Cy7</td>
<td>Clone 53-6.7</td>
<td>100714</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>CD25-PerCP/Cy5.5</td>
<td>Clone PC61</td>
<td>102030</td>
<td>Biolegend</td>
</tr>
<tr>
<td></td>
<td>FoxP3-APC</td>
<td>Clone FJK-16s</td>
<td>17-5773</td>
<td>eBioscience</td>
</tr>
</tbody>
</table>

Figure 1. Food intake and weight gain in IH and RA-exposed mice treated with either Resv or Veh for 8 weeks. A, Mean food intake per mouse/d over 8 weeks; green color indicates IH and open circles indicate Resv treatment. Two-way ANOVA (treatment × condition) F statistic = 8.18; P < .001. B, Mean overall daily food intake for the 8-week period per mouse; P < .001. C, Mean weekly changes in body weight over the 8-week period; two-way ANOVA (treatment × condition) F statistic = 12.74; P < .001. D, Overall changes in body weight; P < .001. E, Mean weights of Epi fat pads; P < .001, n = 12–24/treatment group.
However, IH-Veh-exposed mice showed overall reduced food intake compared with all other groups (Figure 1B). IH-Veh mice displayed poorest weight at the end of the 8-week period, with IH-Resv-exposed mice showing improved weight gain, albeit still lower than RA-treated mice (n = 24 mice/treatment group; P < .001) (Figure 1C and D). Notably, IH-Veh-exposed mice showed most significant reductions in epididymis fat pad weights with some recovery occurring in IH-Resv (n = 12/group) (Figure 1E).

**Effect of Resv on systemic insulin and leptin levels and on visceral adipose tissue insulin resistance**

Overall fasting glycemic levels were similar across the 4 treatment groups. However, in IH-Veh mice, higher fasting HOMA levels due to higher insulin levels emerged after 8 weeks of IH, with such changes being abrogated in IH-Resv-treated mice (Figure 2). Similarly, plasma leptin levels were unaltered in IH-Veh mice compared with RA-exposed groups, but IH-Rev mice showed markedly reduced plasma leptin levels (Figure 2).

Insulin sensitivity in VWAT, as assessed by Akt phosphorylation in response to insulin in both Mes and Epi adipose tissue depots, indicated the presence of insulin resistance after 8 weeks of IH but only in IH-Veh-treated mice. Overall, the findings were very similar for either Mes or Epi. In contrast, there were significant improvements in adipose tissue insulin sensitivity in IH-exposed mice treated with Resv (n = 8/treatment group) (Figure 2).

**Resv protects from IH-induced increases in macrophages and polarization in VWAT**

IH for a period of 8 weeks induced marked increases in the global number of macrophages present in the SVF of both Mes and Epi (Figure 3). Such increases consisted primarily of increases in the proportion of macrophages exhibiting the proinflammatory M1 phenotype (CD11c+; n = 8/group, P < .01) (Figure 3) and reciprocal reductions in macrophages with M2 polarity (CD206+; n = 8/group, P < .01) (Figure 3), such that the M1 to M2 ratio was markedly increased after IH (n = 8/group; P < .01) (Figure 3). IH-induced changes
in Mes and Epi VWAT depot macrophages were markedly attenuated in Resv-treated mice exposed to IH.

Discussion

This study confirms previous findings that chronic IH exposures imposed during the predominant sleep period in mice lead to the emergence of systemic insulin resistance and increased VWAT inflammation (11–18). Furthermore, we now show that treatment with Resv improved the reduced food intake patterns and weight gain associated with IH-exposures and restored insulin responsiveness while normalizing the inflammatory processes within VWAT depots. Furthermore, Resv administration was associated with marked reductions in circulating leptin levels, suggesting increased leptin receptor sensitivity.

Before we discuss some of the major implications of our findings, some methodological issues deserve specific mention. First, we have implemented an IH experimental paradigm that provides highly reproducible findings and, most importantly, mimics frequently encountered patterns of episodic hypoxia occurring in diseases such as OSA (15). In this context, the initial prominent reductions in food consumption and overall diminished nutrient intake exhibited by IH-exposed mice is similar to that previously reported by us (15) as well as by others (42) and may reflect relative leptin receptor resistance induced by IH in the context of an overall catabolic state (43). Notably, Resv treatment improved IH-mediated deceleration in weight gain during the duration of the experiments, suggesting that the both central and peripheral metabolic and orexigenic pathways modulated by IH are affected by this compound, an effect that is not apparent during normoxic conditions. Secondly, as in previous studies (15), we opted not to expose mice to a high-fat diet regimen or to use transgenic mouse models of obesity or insulin resistance, because we aimed to examine the isolated effects of Resv on IH-induced metabolic dysfunction. Thirdly, we exposed our mice to a realistic and implementable yet relatively higher dose of Resv that has already exhibited favorable outcomes in either metabolic or low-grade chronic inflammatory processes (44–47). There is no doubt that future studies, possibly in patients with sleep apnea, can investigate whether Rev supplements at lower doses effectively translate into similar results as those described here. Finally, we should point out that this study was observational in nature and therefore does not provide insights into which of the multiple mechanisms that have been attributed to Resv effects (33–39) was predominantly involved in current findings. Notwithstanding, the current experimental approach convincingly indicates that IH mimicking the episodic hypoxia of sleep apnea induces adipose tissue dysfunction, macrophage infiltration, and phenotypic shift, as well as insulin resistance, all of which are ameliorated by administration of Resv.

Notably, although Resv treatment did not completely restore the overall reduced food intake and weight gain associated with IH, it reversed both systemic and insulin resistance. Thus, the potential use of Resv as a dietary supplement in patients with OSA who also manifest sub-clinical evidence of insulin resistance may ultimately improve metabolic control and potentially prevent the increased incidence of diabetes in this population (20). Furthermore, the beneficial impact of Resv on the inflamm-
flammatory phenotype of the SVF of 2 VWAT depots would suggest that the increased activation of inflammatory pathways elicited by IH (18, 49) was reversed by administration of Resv. Notably the effects of IH and those of Resv treatment were remarkably similar in both adipose tissue depots. We here not only explored a previously described inflammatory pathway, namely macrophages, but also their polarity shifts. The compelling evidence supporting a major role for adipose tissue macrophage infiltration in the context of obesity and metabolic derangements is mimicked by chronic IH in the absence of an obesogenic diet. We can further infer based on the putative roles of macrophage phenotypes (50) that the magnitude of the primarily M1 macrophage infiltration, along with the reciprocal M2 macrophage reduction, is a major determinant of the degree of insulin resistance induced by long-term IH (51–55). Indeed, concurrent with the increased presence of macrophages in IH-exposed adipose tissues, a phenomenon that may be mediated by transcription factors such as hypoxia-inducible factors or nuclear factor κB (27, 48, 56), there was also a shift in their phenotypes, such that increased populations of M1 macrophages along with reduced M2 macrophage cell counts occurred and were reversed by administration of Resv.

Thus, our current findings conclusively confirm that chronic IH, a frequent occurrence in the context of OSA and other respiratory diseases, is an important contributor to the metabolic dysfunction associated with these disorders, most likely via effects on visceral adipose tissue, even when food intake is reduced. Furthermore, we have shown that concurrent administration of Resv improves the reductions in food intake and weight gain and is particularly effective at reversing the metabolic disturbances induced by IH, most likely by abrogating visceral adipose tissue inflammation. Thus, regular use of dietary supplements, such as Resv, may provide a useful adjunct therapy aimed at reducing the early stages of metabolic dysfunction in OSA.

Acknowledgments

Address all correspondence and requests for reprints to: David Gozal, Department of Pediatrics, Pritzker School of Medicine, The University of Chicago, 5721 South. Maryland Avenue, MC8000, K160, Chicago, IL 60637-1470. E-mail: dgozal@uchicago.edu.

This work was supported by the Herbert T. Abelson Endowed Chair in Pediatrics (D.G.).

Disclosure Summary: The authors have nothing to disclose.

References


